Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters- On Demand

ACCP Virtual Journal Club Webinars

On Demand: August 18, 2021 to August 18, 2024

See Handouts tab for Continuing Education information on IPCE credits.

Why is this webinar important to you? 

This webinar presents the bridging through pharmacokinetic/pharmacodynamic modeling the in vitro binding affinity to in vivo receptor occupancy and the potential association with clinical parameter improvements of sarilumab and tocilizumab in patients with rheumatoid arthritis. The study evaluated the in vitro binding of sarilumab and tociluzumab to interleukin (IL)-6Rα and inhibition of signaling and the association between IL-6Rα receptor occupancy and C-reactive protein (CRP) and potential clinical relevance of differences. 

Target Audience
Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.

Learning Objectives
After completing this activity, the learner will be able to: 

1) Articulate the mechanism of action of sarilumab and tocilizumab and the downward physiologic effects;
2) Differentiate the binding affinity of sarilumab and tocilizumab to IL-6Rα compared to placebo;
3) Evaluate the expected response to CRP levels and the expected clinical response based on dosage and usage of sarilumab and tocilizumab.

To receive credit, learners must attend the complete live webinar or view the complete on-demand webinar; complete a post-course assessment and evaluation.